Shares of Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) dropped 4.6% on Tuesday . The company traded as low as $4.15 and last traded at $4.16, with a volume of 109,115 shares. The stock had previously closed at $4.36.

TTPH has been the topic of a number of research reports. BMO Capital Markets initiated coverage on Tetraphase Pharmaceuticals in a research report on Monday, April 11th. They set a “market perform” rating and a $8.00 price target on the stock. Zacks Investment Research cut Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, July 14th. Wedbush dropped their price target on Tetraphase Pharmaceuticals from $8.00 to $4.00 and set an “outperform” rating on the stock in a research report on Friday, May 13th. Gabelli reiterated a “neutral” rating on shares of Tetraphase Pharmaceuticals in a research report on Monday, May 16th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Tetraphase Pharmaceuticals in a research report on Saturday, May 14th. Twelve analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Tetraphase Pharmaceuticals has an average rating of “Hold” and an average price target of $20.80.

The stock’s 50-day moving average is $4.18 and its 200 day moving average is $4.74. The stock’s market cap is $156.49 million.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by $0.02. The company earned $2 million during the quarter, compared to analyst estimates of $2.20 million. During the same quarter in the previous year, the business posted ($0.66) earnings per share. The firm’s quarterly revenue was down 33.3% compared to the same quarter last year. On average, equities analysts predict that Tetraphase Pharmaceuticals Inc. will post ($1.96) earnings per share for the current year.

A hedge fund recently raised its stake in Tetraphase Pharmaceuticals stock. California Public Employees Retirement System increased its position in shares of Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) by 1,459.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 276,000 shares of the biopharmaceutical company’s stock after buying an additional 258,300 shares during the period. California Public Employees Retirement System owned about 0.76% of Tetraphase Pharmaceuticals worth $2,768,000 as of its most recent SEC filing.

Tetraphase Pharmaceuticals, Inc (Tetraphase) is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. It is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.